These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 18946539)

  • 1. Altered Excitatory-Inhibitory Balance in the NMDA-Hypofunction Model of Schizophrenia.
    Kehrer C; Maziashvili N; Dugladze T; Gloveli T
    Front Mol Neurosci; 2008; 1():6. PubMed ID: 18946539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia.
    Jentsch JD; Roth RH
    Neuropsychopharmacology; 1999 Mar; 20(3):201-25. PubMed ID: 10063482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta and Gamma Oscillations in Prefrontal Cortex During NMDA Hypofunction: An In Vitro Model of Schizophrenia Features.
    Rebollo B; Perez-Zabalza M; Ruiz-Mejias M; Perez-Mendez L; Sanchez-Vives MV
    Neuroscience; 2018 Jul; 383():138-149. PubMed ID: 29723576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.
    Lindsley CW; Shipe WD; Wolkenberg SE; Theberge CR; Williams DL; Sur C; Kinney GG
    Curr Top Med Chem; 2006; 6(8):771-85. PubMed ID: 16719816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia.
    Chavez-Noriega LE; Schaffhauser H; Campbell UC
    Curr Drug Targets CNS Neurol Disord; 2002 Jun; 1(3):261-81. PubMed ID: 12769619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.
    Engel M; Snikeris P; Matosin N; Newell KA; Huang XF; Frank E
    Psychopharmacology (Berl); 2016 Apr; 233(8):1349-59. PubMed ID: 26861891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic brain network reconfiguration as a potential schizophrenia genetic risk mechanism modulated by NMDA receptor function.
    Braun U; Schäfer A; Bassett DS; Rausch F; Schweiger JI; Bilek E; Erk S; Romanczuk-Seiferth N; Grimm O; Geiger LS; Haddad L; Otto K; Mohnke S; Heinz A; Zink M; Walter H; Schwarz E; Meyer-Lindenberg A; Tost H
    Proc Natl Acad Sci U S A; 2016 Nov; 113(44):12568-12573. PubMed ID: 27791105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short and long term changes in NMDA receptor binding in mouse brain following chronic phencyclidine treatment.
    Newell KA; Zavitsanou K; Huang XF
    J Neural Transm (Vienna); 2007; 114(8):995-1001. PubMed ID: 17401537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the mGluR allosteric modulation in the NMDA-hypofunction model of schizophrenia.
    Doreulee N; Alania M; Mitaishvili E; Chikovani M; Chkhartishvili B
    Georgian Med News; 2009 Dec; (177):59-65. PubMed ID: 20090156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia.
    Greene R
    Hippocampus; 2001; 11(5):569-77. PubMed ID: 11732709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia.
    Steullet P; Neijt HC; Cuénod M; Do KQ
    Neuroscience; 2006 Feb; 137(3):807-19. PubMed ID: 16330153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local NMDA receptor hypofunction evokes generalized effects on gamma and high-frequency oscillations and behavior.
    Lee J; Hudson MR; O'Brien TJ; Nithianantharajah J; Jones NC
    Neuroscience; 2017 Sep; 358():124-136. PubMed ID: 28676240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational study of NMDA conductance and cortical oscillations in schizophrenia.
    Kirli KK; Ermentrout GB; Cho RY
    Front Comput Neurosci; 2014; 8():133. PubMed ID: 25368573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comorbidity of substance abuse with other psychiatric disorders.
    Palomo T; Archer T; Kostrzewa RM; Beninger RJ
    Neurotox Res; 2007 Jul; 12(1):17-27. PubMed ID: 17513197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment.
    Laruelle M; Kegeles LS; Abi-Dargham A
    Ann N Y Acad Sci; 2003 Nov; 1003():138-58. PubMed ID: 14684442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered avalanche dynamics in a developmental NMDAR hypofunction model of cognitive impairment.
    Seshadri S; Klaus A; Winkowski DE; Kanold PO; Plenz D
    Transl Psychiatry; 2018 Jan; 8(1):3. PubMed ID: 29317600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained NMDA receptor hypofunction induces compromised neural systems integration and schizophrenia-like alterations in functional brain networks.
    Dawson N; Xiao X; McDonald M; Higham DJ; Morris BJ; Pratt JA
    Cereb Cortex; 2014 Feb; 24(2):452-64. PubMed ID: 23081884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The acute effects of NMDA antagonism: from the rodent to the human brain.
    Gunduz-Bruce H
    Brain Res Rev; 2009 May; 60(2):279-86. PubMed ID: 18703087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NMDA hypofunction in the posterior cingulate as a model for schizophrenia: an exploratory ketamine administration study in fMRI.
    Northoff G; Richter A; Bermpohl F; Grimm S; Martin E; Marcar VL; Wahl C; Hell D; Boeker H
    Schizophr Res; 2005 Jan; 72(2-3):235-48. PubMed ID: 15560968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.